Fundraising Fox
Aulos Bioscience
Cambridge, US · Founded 2020 · Delaware corporation · 15 employees on LinkedIn
Find your way into Aulos Bioscience
Sign up to see every warm intro you have to Aulos Bioscience
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Aulos Bioscience team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Aulos develops an immune-activating monoclonal antibody therapeutic for cancer, using AI to design an antibody targeting the IL-2 portion that interacts with the CD25 receptor to shift IL-2 activity toward immune activation. Its lead investigational candidate, imneskibart, is in a Phase 1/2 clinical trial for solid tumor cancers including melanoma and renal cell carcinoma.
Founders & leadership
Aulos Bioscience was founded in 2020 by Yanay Ofran.
YO
Yanay OfranCo-Founder and CSOYanay Ofran holds a Ph.D. in Molecular Biophysics and Biomedical Informatics from Columbia University and previously served as a professor of bioinformatics at Bar-Ilan University in Israel; he is co-founder and Chief Scientific Officer of Aulos Bioscience, which develops AI-designed immunotherapies for cancer, and also founded Biolojic Design and co-founded Ukko, a biotech company focused on protein design for food and agriculture.
JY
Joseph YanchikNamed on SEC filing
YB
Yechezkel BarenholzNamed on SEC filing
MP
Micah PearlmanNamed on SEC filing
Board
Reported raises · per SEC filings
Form D private placements$20M disclosed across 2 rounds · 2020–2023
▶$5MraisedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Seth HarrisonDirector
- Rajesh ChopraDirector
- Anna BatarinaDirector
- Aron KnickerbockerExecutive Officer, Director
- James VasselliExecutive Officer
- Michael EhlersDirector
- Mace RothenbergDirector
- Yanay OfranDirector
- Leo J. RedmondExecutive Officer
- Offering amount
- $20M
- Amount sold
- $5M
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$15MraisedNov 2020 · 1 investors · BiotechnologyRule 506(b)
▶$15MraisedNov 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael EhlersExecutive Officer, Director
- Rajesh ChopraDirector
- Joseph YanchikDirector
- Yanay OfranExecutive Officer, Director
- Yechezkel BarenholzDirector
- Micah PearlmanExecutive Officer
- Offering amount
- $40M
- Amount sold
- $15M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
AlloyAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.
Applied TherapeuticsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Cerecor Inc.Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Its pipeline includes abdakibart (AVTX-009), tested in a Phase 2 trial for hidradenitis suppurativa, and AVTX-010, a long-acting next-generation anti-IL-1β antibody.
AlumisAlumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases. It focuses on small-molecule drug discovery and development in immunology and inflammation.
Talus BioTalus develops a proprietary platform that measures and modulates the regulome—the body's gene expression control system—in native cellular contexts. The company designs AI-driven compounds and uses functional proteomics to enable drug discovery for transcription factors and regulatory proteins implicated in oncology, rare disease, and immune dysfunction.
Companies working in the same space as Aulos Bioscience.
Frequently asked questions
- What does Aulos Bioscience do?
- Aulos develops an immune-activating monoclonal antibody therapeutic for cancer, using AI to design an antibody targeting the IL-2 portion that interacts with the CD25 receptor to shift IL-2 activity toward immune activation. Its lead investigational candidate, imneskibart, is in a Phase 1/2 clinical trial for solid tumor cancers including melanoma and renal cell carcinoma.
- Who founded Aulos Bioscience?
- Aulos Bioscience was founded by Yanay Ofran in 2020.
- How much funding has Aulos Bioscience raised?
- Aulos Bioscience has disclosed $20M raised across 2 rounds.
- Where is Aulos Bioscience headquartered?
- Aulos Bioscience is headquartered in Cambridge, US.